Highlights and Quick Summary
- Total liabilities for the quarter ending September 30, 2022 was $1.86 Billion (a -0.96% decrease compared to previous quarter)
- Year-over-year quarterly Total liabilities decreased by -1.01%
- Annual Total liabilities for 2021 was $1.88 Billion (a 214.7% increase from previous year)
- Annual Total liabilities for 2020 was $597 Million (a 278.19% increase from previous year)
- Annual Total liabilities for 2019 was $158 Million (a 80.1% increase from previous year)
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Total liabilities of BridgeBio Pharma, Inc.
Most recent Total liabilitiesof BBIO including historical data for past 10 years.Interactive Chart of Total liabilities of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. Total liabilities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $1,859.0 | $1,877.0 | $1,854.0 | – |
| 2021 | $1,878.0 | $1,517.0 | $1,538.98 | $1,482.67 | $1,879.79 |
| 2020 | $597.33 | $571.88 | $579.62 | $540.78 | $597.33 |
| 2019 | $157.95 | $118.83 | $0.0 | $0.0 | $157.95 |
| 2018 | – | – | $87.7 | $0.0 | $87.7 |
| 2017 | $0.0 | – | – | – | $0.0 |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology